azd8683
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT00979849)
Timeline
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545222 ↗
Also known as
- azd8683
- azd8683
- azd-8683
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01666613 | Phase 1 | Nov 1, 2012 | AstraZeneca |
| NCT01708057 | Phase 2 | Oct 1, 2012 | AstraZeneca |
| NCT01584739 | Phase 1 | Jun 1, 2012 | AstraZeneca |
| NCT01419600 | Phase 1 | Oct 1, 2011 | AstraZeneca, IQVIA |
| NCT01205269 | Phase 2 | Oct 1, 2010 | AstraZeneca |
| NCT00979849 | Phase 1 | Oct 1, 2009 | AstraZeneca |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 2 | 2009 |
| IQVIA | For profit | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1